EDDC is proud to share that we are embarking on a partnership with ImmunoScape to develop novel T cell receptor-based therapeutics! 

Under the terms of the agreement, ImmunoScape will contribute their repertoire of highly potent tumor-specific TCR candidates to EDDC’s expertise in therapeutic protein design and antibody engineering, to jointly develop innovative off-the-shelf TCR-based bispecific molecules. 

We look forward to working with ImmunoScape to develop molecules for sensitive and effective tumor targeting in a T cell-independent manner.

Read the full press release here!